Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...

Pulmonary Edema II: Pathophysiology

Pulmonary Edema II: Pathophysiology

Pulmonary edema is the accumulation of fluid in the interstitial and alveolar spaces of the lungs, impairing gas exchange and oxygen delivery. It may be cardiogenic or noncardiogenic, but both reduce oxygenation and lung compliance.Cardiogenic Pulmonary EdemaCardiogenic edema results from increased hydrostatic pressure in pulmonary capillaries, usually due to left ventricular dysfunction from myocardial infarction, heart failure, or valvular disease. Ineffective cardiac pumping causes blood to...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Blood Pressure Imbalances and Circulatory Shock

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

Acute Inflammation III: Local and Systemic Effects

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sulforaphane reduces advanced glycation end products (AGEs)-induced inflammation in endothelial cells and rat aorta.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2016

Same author

Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2014

Same author

Positive association of serum levels of pigment epithelium-derived factor with high-sensitivity C-reactive protein in apparently healthy unmedicated subjects.

The Journal of international medical research·2010

Same author

Pathophysiological role of pigment epithelium-derived factor (PEDF) in hepatic disorders.

Current medicinal chemistry·2010

Same author

Development of enzyme-linked immunosorbent assay system for PEDF and its clinical utility.

Current molecular medicine·2010

Same author

Structure-function relationships of PEDF.

Current molecular medicine·2010

Search research articles

Related Experiment Video

Updated: Jun 15, 2026

Lipopolysaccharide Infusion as a Porcine Endotoxemic Shock Model

Lipopolysaccharide Infusion as a Porcine Endotoxemic Shock Model

Published on: December 8, 2023

PEDF and septic shock.

T Nakamura¹, S-I Yamagishi

¹Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Chiba, Japan.

Current Molecular Medicine

|March 19, 2010

Summary

This summary is machine-generated.

Septic shock treatment using Polymyxin B-immobilized fiber (PMX-F) shows promise. This review explores PMX-F

Related Experiment Videos

Last Updated: Jun 15, 2026

Lipopolysaccharide Infusion as a Porcine Endotoxemic Shock Model

Lipopolysaccharide Infusion as a Porcine Endotoxemic Shock Model

Published on: December 8, 2023

Area of Science:

Critical care medicine
Immunology
Biochemistry

Background:

Septic shock is a major cause of death, with endotoxin playing a key role.
Existing therapies have limited success, leading to interest in extracorporeal treatments.
Polymyxin B-immobilized fiber (PMX-F) removes endotoxin via adsorption.

Purpose of the Study:

To review the pathogenesis of septic shock.
To discuss the clinical utility and effects of PMX-F treatment.
To explore the role of Pigment epithelium-derived factor (PEDF) in septic shock.

Main Methods:

Literature review of septic shock pathogenesis.
Analysis of clinical data on PMX-F treatment efficacy and safety.
Discussion of PEDF's pathophysiological role and potential as a biomarker.

Main Results:

PMX-F treatment is reported as safe and effective in Japanese clinical studies.
PEDF exhibits anti-oxidative and anti-inflammatory properties.
PEDF may modulate inflammatory reactions and serve as a septic shock biomarker.

Conclusions:

PMX-F offers a potential therapeutic strategy for septic shock by reducing endotoxin levels.
PEDF's role in septic shock warrants further investigation.
Understanding the interplay between PEDF, endotoxin, and HMGB1 is crucial.